The role of gamma-synuclein in cocaine-induced behaviour in rats by Boyer, Frederic & Dreyer, Jean-Luc
The role of gamma-synuclein in cocaine-induced
behaviour in rats
Frederic Boyer and Jean-Luc Dreyer
Institute of Biochemistry, University of Fribourg, Rue du Muse´e 5, CH-1700 Fribourg, Switzerland
Keywords: addiction, cocaine, drugs of abuse, gamma-synuclein, in vivo gene transfer, lentivirus, siRNA
Abstract
The aim of this study was to investigate the role of c-synuclein in the rewarding effects of chronic cocaine administration and its
putative interaction with the dopamine transporter (DAT). For this purpose, regulatable lentiviruses driving overexpression of the rat
c-synuclein or DAT have been prepared, as well as lentiviruses expressing siRNAs, aimed at silencing either DAT or c-synuclein
mRNA expression. Overexpression of DAT in the nucleus accumbens (NAc) induced a 35% decrease in locomotor activity, which
could be abolished when the same animal was fed doxycycline. Furthermore, local inhibition of DAT in the NAc, using lentiviruses
expressing siRNAs targeted against DAT, resulted in signiﬁcant hyperlocomotion activity (72% increase over controls). By contrast,
overexpression of c-synuclein in the NAc alone had no effect, while local silencing lead to a signiﬁcant decrease in cocaine-induced
locomotor activity (47% decrease compared with controls). Surprisingly, coinjection lentiviruses expressing DAT and
c-synuclein ) leading to overexpression of both proteins in the NAc ) resulted in a strong increase in cocaine-induced rat
locomotor activity (52% increase compared with controls), which was abolished upon locally silencing these genes, suggesting a
synergetic role of both proteins, possibly mediated through a direct interaction.
Introduction
Cocaine is a major psychostimulant, which binds to the dopamine
transporter (DAT) and blocks the synaptic reuptake of dopamine
leading to a marked elevation of synaptic dopamine. This may be
responsible for mediating behavioural and reinforcing effects that
contribute to its abuse liability. The shuttling of DAT to and away
from the plasma membrane is modiﬁed by the action of a-synuclein,
thereby changing the efﬁciency of dopamine uptake at the nerve
terminals (Sidhu et al., 2004b), e.g. in the mesolimbic dopaminergic
system, a critical pathway mediating addiction to psychostimulant and
reinforcement. a-Synuclein binds to the DAT and serotonin trans-
porter, affecting their activities and their recruitment to the plasma
membrane, an effect that can be modulated by c-synuclein expression
(Wersinger et al., 2003a,b, 2006; Wersinger & Sidhu, 2005).
Synucleins are small proteins, mainly expressed in neurons. Little is
known about their normal functions, although some evidence suggests
a role on synaptic vesicular transport and synaptic plasticity (Murphy
et al., 2000; Li et al. 2002). They play an important role as regulator in
dopaminergic transmission (Abeliovich et al., 2000; Mosharov et al.,
2006) and regulate the ﬁlamentous network that in turn inﬂuences the
release of dopamine and glutamate neurotransmitters involved in the
mood and motivation process. The family includes three known
proteins: a-synuclein, b-synuclein and c-synuclein (Li et al., 2002).
The role of a-synuclein in the genesis of neurodegenerative disorders
is well known, whereas the other members of the synuclein family are
less characterized. a- and c-Synuclein are involved in dopamine
homeostasis, as both proteins bind to tyrosine hydroxylase (Perez
et al., 2002; Xu et al., 2002) and other dopamine synthesis genes, such
as GTP cyclohydrolase (Sidhu et al., 2004a), downregulating their
activities (Kuhn et al., 2007). c-Synuclein is overexpressed in breast
cancer cells, where it upregulates matrix proteases (Surgucheva et al.,
2003; Jiang et al., 2004) and plays a principal role in neuronal
plasticity in the population of neurons involved in an adapted
integration of mood response to environmental challenges (Kuhn
et al., 2007). It is also involved in cell migration and adhesion (Jia
et al., 1999), in ocular pathologies (Surguchov et al. 2001a, 2001b;
Maurage et al., 2003) and some forms of neurodegeneration (Galvin
et al., 1999, 2000; Wang et al., 2004). In addition, c-synuclein
inﬂuences neuroﬁlament network integrity in cultured sensory neurons
(Buchman et al., 1998) and activates Elk-1, mitogen-activating kinase
and several types of matrix metalloproteases (Surguchov et al.,
2001a), thus playing a role in remodelling of extracellular matrix and
modulating axonal architecture, which are central also in addiction.
In a previous study, we have described an overexpression of a- and
mainly of c-synuclein in the mesolimbic dopaminergic pathway upon
cocaine (Brenz-Verca et al., 2003), suggesting a key role in regulating
this brain circuit upon addiction. Because a-synuclein strongly
controls the expression of the DAT transporter at the plasma
membrane, a process modulated by c-synuclein, we aimed in the
present study at investigating the role of c-synuclein in the rewarding
effects of chronic cocaine administration in relation to DAT expres-
sion. For this purpose, lentiviruses driving the expression of the rat
DAT or of c-synuclein or expressing siRNAs targeted against either
DAT or c-synuclein mRNA were constructed and served for in vivo
gene transfer into the rat nucleus accumbens (NAc). The impact of
c-synuclein and DAT expression on chronic cocaine administration
was assessed under different conditions, using locomotor activity
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measurements. Our data suggest a synergic role of both proteins,
which could pass through a direct interaction.
Materials and methods
Lentivirus constructions
Construction of lentivirus-c-synuclein (LV-cSyn)
The rat c-synuclein cDNA (GenBank accession no. 031688) was
polymerase chain reaction (PCR) -ampliﬁed from cDNA of cocaine-
injected rats using the following primers: 5¢-AAG GAT CCA ATG
GGT TAC CCATAC GAC GTC CCC AGA CTA CGC TAT GGA
CGT CTT CAA T-3¢ and 5¢-CCG CTC GAG CGG ATG AGT AAG
AGC AAA-3¢. The forward primer contains a BamHI restriction site
followed by the haemaglutinin epitope sequence (in bold) and the rat
5¢-c-synuclein cDNA speciﬁc sequence, the reverse primer contains
the rat 3¢-c-synuclein cDNA-speciﬁc sequence, a stop codon and a
XhoI restriction site. The PCR product was digested with BamHI and
XhoI and cloned into BamHI ⁄ XhoI restriction sites into pTK431 (Bahi
et al., 2005), which expresses the gene of interest under control of a
Tet-Off promotor. The green ﬂuorescent protein (GFP) expression
vector pTK433 (Bahi et al., 2004a,b) was used as a control vector.
Construction of lentiviruses-c-synuclein-siRNAs (LV-cSyn-siRNAs)
To silence c-synuclein expression in vitro and in vivo, three targets
were designed according to the c-synuclein mRNA sequence. The
following targets within the c-synuclein sequence were selected, based
on Hannon’s design criterion (http://katahdin.cshl.org:9331/RNAi/
html/rnai.html): ﬁrst target: bp 21–52; second target: bp 184–212;
third target: bp 342–368. To each oligo, a XhoI restriction site was
added at 3¢ and a U6-3¢-speciﬁc 10mer at 5¢. Using the pSilencer
1.0-U6 (Ambion, UK) as a template and a U6 promoter-speciﬁc
forward primer containing BamHI restriction site (5¢-GCG GAT CCC
GCT CTA GAA CTA GTG C-3¢), each siRNA target was added to the
mouse U6 promoter by PCR, using the following PCR program: 120 s
at 94 C (initial denaturation) followed by 35 cycles (45 s at 94 C,
45 s at 64 C and 45 s at 72 C) in 4% dimethyl sulphoxide (Sigma,
Switzerland). The PCR product was digested with BamHI and XhoI,
cloned into similar sites into pTK431, and sequenced to verify the
integrity of each construct.
Construction of lentivirus-DAT (LV-DAT)
The DAT DNA (GenBank accession no. 012694) was PCR ampliﬁed
from pCMV5rDAT as a template and the following primers: 5¢-CCG
TTA ACATGG ACTACA AAG ACG ATG ACG ATA AGC CAG
TAA GAG CAA ATG C-3¢ and 5¢-CCG CTC GAG CGG TTA CAG
CAA CAG CCA GTG ACG-3¢. The forward primer contains a HpaI
restriction site followed by a FLAG epitope sequence (in bold) and the
rat 5¢ DAT cDNA speciﬁc sequence, the reverse primer contains the rat
3¢ DAT cDNA-speciﬁc sequence, a stop codon and a XhoI restriction
site. The PCR product was digested with HpaI and XhoI, and cloned
into HpaI ⁄ XhoI restriction sites into pTK431 (Bahi et al., 2005),
which expresses the gene of interest under control of a Tet-Off
promotor. The GFP expression vector pTK433 (Bahi et al., 2004a,b)
was used as a control vector.
Construction of lentiviruses DAT-siRNAs (LV-siRNAs-DAT)
To silence DAT expression in vitro and in vivo, three targets were
designed according to the DAT mRNA sequence. The following
targets within the DAT sequence were selected, based on Hannon’s
design criterion (http://katahdin.cshl.org:9331/RNAi/html/rnai.html):
ﬁrst target: bp 19–47; second target: bp 864–890; third target:
bp1827–1854. To each oligo, a XhoI restriction site was added at 3¢
and a U6-3¢-speciﬁc 10mer at 5¢. Using the pSilencer 1.0-U6
(Ambion, UK) as a template and a U6 promoter-speciﬁc forward
primer containing BamHI restriction site (5¢-GCG GAT CCC GCT
CTA GAA CTA GTG C-3¢), each siRNA target was added to the
mouse U6 promoter by PCR, using the following PCR program: 120 s
at 94 C (initial denaturation) followed by 35 cycles (45 s at 94 C,
45 s at 64 C and 45 s at 72 C) in 4% dimethyl sulphoxide (Sigma).
The PCR product was digested with BamHI and XhoI, cloned into
similar sites into pTK431, and sequenced to verify the integrity of
each construct.
Lentivirus production
The vector plasmids (either pTK431-c-synuclein, pTK431-DAT,
pTK433-GFP, pTK431-U6-cSyn-siRNAs, pTK431-U6-DAT-siR-
NAs), together with the packaging construct plasmid pÆNRF and the
envelope plasmid pMDG-VSV-G were co-transfected into human
embryonic kidney 293T cells (HEK293T) to produce the viral particles
(Bahi et al., 2004a,b). The viral titres were determined by p24 antigen
measurements (KPL, USA). For the in vivo experiments, the different
viral stocks were matched for viral particle content and used at
0.2 mg ⁄mL of p24, corresponding to 8 · 109 infectious parti-
cles ⁄mL.
In vitro assays of LV-cSyn and LV-DAT
The efﬁciency of the LV-cSyn and LV-DAT were tested in vitro by
infection of HEK293T cells: 1 · 105 HEK293T cells were plated per
well in six-well plates. The next day, lentiviruses stocks were mixed
with 4 lg ⁄mL Polybrene (Sigma, Buchs, Switzerland) with ⁄without
30 ng ⁄mL doxycycline (Sigma), incubated for 30 min at room
temperature, added to the cells and incubated at 37 C. After 24 h
the medium was replaced with normal growth medium (with or
without 30 ng ⁄mL doxycycline) and cells were left for a further 48 h.
Cells were then collected and used for total RNA isolation (for real-
time PCR) or for total protein isolation (for Western blot). Infections
with the different lentiviruses were done as follows: (a) doxycycline
regulation: cells were co-infected using 0, 2, 4 or 8 lL of LV-cSyn or
LV-DAT stock, and one part of the cells was incubated in the presence
of 30 ng ⁄mL doxycycline and the other part without doxycycline; (b)
in vitro silencing of c-synuclein: cells were infected with 2 lL of LV-
cSyn stock, either alone or together with 0.5, 1, 2 or 4 lL of a mix of
the three LV-cSyn-siRNAs (mix of LV-cSyn-siRNAs-T1, LV-cSyn-
siRNAs-T2 and LV-cSyn-siRNAs-T3); (c) in vitro silencing of DAT:
cells were infected with 2 lL of LV-DAT stock, either alone or
together with 0.5, 1, 2 or 4 lL of a mix of the three LV-DAT-siRNAs
(mix of LV-DAT-siRNAs-T1, LV-DAT-siRNAs-T2 and LV-DAT-
siRNAs-T3).
Quantitative real-time PCR and quantiﬁcation of c-synuclein
transcripts
For quantitative real-time PCR, primer sets for rat c-synuclein, DAT,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or cyclophilin
F were designed to amplify 100- to 200-bp products, using PRIMER3
software: (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_http://www.
cgi). The following speciﬁc primer pairs were used: for rat c-synuc-
lein: 5¢-CGT CAA CAC AGT GGC CACC-3¢ and 5¢-GGT TCC AAG











GCA-3¢ and 5¢-TGA CCA CGA CCA CAT ACA GG-3¢; for rat
GAPDH: 5¢-ATG ACT CTA CCC ACG GCA AG-3¢ and 5¢-CATACT
CAG CAC CAG CAT CAC-3¢; for rat cyclophilin F: 5¢-GTG AGA
AGG GCT TTG GCT AC-3¢ and 5¢-TTC TCG TCA GGA AAG
CGG-3¢. GAPDH and cyclophilin F were used as endogenous controls
for normalization. No difference in expression was observed between
these two genes in all quantiﬁcations.
Total RNA was extracted from the HEK293T cells (for in vitro
quantiﬁcation) and from brains of cocaine-treated animals (for in vivo
quantiﬁcation) using TRIzol Reagent (Invitrogen, Switzerland),
including an RNase-free DNase step. RNA was quantiﬁed by
spectrophotometry, and its integrity veriﬁed by agarose gel electro-
phoresis as visualized with ethidium bromide staining. First strand
cDNA was generated from 2 lg of total RNA and Oligo(dT12-18)-
primer with the M-MLV reverse transcription kit (Invitrogen, Basel,
Switzerland) in a total volume of 20 lL. The reaction product was
used for quantitative real-time PCR using the real-time PCR iCycler
(Bio-Rad, Reinach, Switzerland). cDNA preparation (2 lL), 0.5 lm
of forward and reverse primers, and 10 lL of IQ SYBR Green
Supermix (Biorad, Reinach, Switzerland) in a total volume of 20 lL
were applied and PCR was performed as follows: 3 min at 95 C
(initial denaturation); 20 C ⁄ s temperature transition rate up to 95 C
for 30 s, 10 s at 55 C and 30 s at 56 C, repeated for 40 cycles
(ampliﬁcation). The PCR reaction was evaluated by melting curve
analysis and by checking the PCR products on 2% agarose gel.
The PCR cycle number at which each assay target reached the
threshold detection line was determined [‘threshold cycles’, (Ct)
value]. The Ct of each candidate was normalized against that of
GAPDH or cyclophilin F. To determine the linearity and detection
limit of the assay, cDNA samples were ampliﬁed for successive
10-fold dilutions in a series of real-time PCRs, using duplicate assay
on each dilution, so that the correlation coefﬁcient could be calculated
from the standard curve of Ct values. Comparisons were made
between cocaine and saline groups, and signiﬁcance was calculated
using two-tailed Student’s t-test and the level of statistical signiﬁcance
was set at P < 0.05. Data were expressed as means ± SEM. The Ct for
each candidate was calculated as: Ct ¼ [Ct (candidate) )Ct (GAPDH
or cyclophilin F)]. The relative abundance of each target in each
protocol can be calculated as the ratio between treated and untreated
samples.
Western blotting
Rat NAc (150–200 mg) or transfected HEK293T cells were homog-
enized in buffer (in mm: Tris, 50, pH 7.5; NaCl, 120; CaCl2, 1.5;
MgCl2, 5; KCl, 5; EDTA, 5) with a protease inhibitor mixture (Sigma,
St Louis, MO, USA; 1 mL ⁄ 20 g of tissue). Homogenates were
solubilized with 1% digitonin, followed by the addition of secondary
solubilization buffer [in mm: Tris, 50, pH 7.6; NaCl, 150; 1%
Nonidet-P40; 0.5% sodium deoxycholate; EDTA, 2; sodium ortho-
vanadate, 1; phenylmethylsulphonyl ﬂuoride (PMSF), 1; 1% Triton
X-100], and centrifuged at 10 000 g at 4 C for 15 min. Solubilized
extracts were subjected to sodium dodecyl sulphate–polyacrylamide
gel electrophoresis (SDS–PAGE). Blots were blocked with 5% non-fat
dried milk dissolved in TBST (in mm: Tris, 10; NaCl, 150; 0.1%
Tween-20) for 1 h at room temperature, and incubated with primary
antibodies for either DAT (1 : 2000; Abcam, UK) or c-synuclein
(1 : 1000; Abcam) overnight at 4 C. Blots were washed three times
with TBST and incubated for 1 h with the peroxidase-conjugated
secondary antibody solution. Proteins were then visualized using
enhanced chemiluminescence (Millipore, Basel, Switzerland). Mem-
branes were washed for 30 min in TBST and placed in stripping
solution (glycine-HCl 25 mm, pH 2.0, 1% SDS) for 30 min and used
as described above for b-actin detection (1 : 4000; Sigma).
Immunohistochemistry
For immunohistochemistry assays, rats were decapitated. Brains were
quickly removed from the skull, immediately frozen in isopentane (at
)30 C for 3 min) and kept at )25 C. Coronal sections were cut at
14 lm in a cryostat and placed on gelatinized glass slides, air-dried at
room temperature for 20 min and kept at )25 C until further
processing. Brain sections were ﬁxed for 10 min in cold acetone and
washed three times in 1 · phosphate-buffered saline (PBS). Non-
binding sites were blocked by incubating slices for 1 h in 1 · PBS
containing 1% bovine serum albumin, 1% Triton X-100 and 3%
normal goat serum. Sections were then incubated overnight at 4 C
with primary antibodies speciﬁcally against either c-synuclein
(1 : 5000; mouse anti-c-synuclein antibody, Abcam) or DAT (rabbit
anti-DAT antibody, Ab1591P, Chemicon, 1 : 5000). Antibodies were
diluted in 1 · PBS containing 0.1% Triton X-100 and 1% normal goat
serum. Thereafter slices were washed three times in 1 · PBS, and
incubated for 2 h in the secondary antibodies (Texas red-conjugated
goat anti-rabbit immunoglobulin G, 1 : 500 and FITC-conjugated or
Texas-conjugated anti-mouse immunoglobulin G, 1 : 500) in 1 · PBS
containing 0.1% Triton X-100. The sections were coverslipped with a
medium containing glycerol in PBS (AF1 mountant solution, Citiﬂu-
or). Negative controls included omission or substitution of primary
antibodies.
Fluorescence microscopy
To observe the stained sections, a multiﬂuorescence microscope
(Axioplan 2 imaging, Zeiss, Germany) was used with a 40 ·
objective. Fluorophores used (Texas red and FITC) were detected
with the appropriate detecting systems (HAL 100). Texas red was
exited by a 570-nm beam and was detected through a light path
ranging 600–660 nm. FITC was excited at 495 nm and was detected
through a light path ranging 510–550 nm. Stained sections were
visualized, photographed using a multichannel camera (Axiocam,
Zeiss, Germany) combined to acquisition software (Axiovision system
3.1) and recorded on CD.
Animal handling and behavioural analysis
Animals used in this experiment were male Wistar rats weighing 250–
280 g. All animal experiments were carried out in accordance with the
guidelines and regulations for Animal Experimentation, BAG, Bern,
Switzerland. The animals were housed four per cage in clear plastic
cages with wire grid lids. Access to food and water was unrestricted.
The animals were kept in the animal facility maintained on a 12 h
light : 12 h dark cycle (lights off at 07.00 h). For doxycycline
treatment, animals were maintained with 0.02% doxycycline (Sigma)
and 5% sucrose supplemented in water. During the gene overexpres-
sion period, animals were maintained only with 5% sucrose.
Stereotaxic surgery
Stereotaxic surgery and injection of the lentiviral vector were
performed according to previous publications (Bahi et al., 2004a,b).











(100 mg ⁄ kg ⁄ 10 mg ⁄ kg, i.p.), placed in a stereotaxic apparatus (KOP
Model 920, Colbourn, USA) and bilaterally injected into the core part
of the NAc with 2 lL or 4 lL of concentrated lentiviral stock
(0.2 mg ⁄mL of p24, corresponding to 8 · 109 IU ⁄mL) using a 10-lL
Hamilton syringe (Hamilton, RN801). The injections were performed
bilaterally at the following coordinates, as calculated from bregma and
the dura mera: anterior +1.4; lateral ±1.4; ventral )6.8 (Paxinos &
Watson, 1998).
Procedures
Experiment 1: effects of DAT on cocaine-induced locomotor activity
Four groups of animals (n ¼ 8) were prepared: one group was
stereotaxically injected with 2 lL of LV-GFP (controls); a second
group was injected with 2 lL of LV-DAT; a third group was injected
with 2 lL of a mix of all three LV-DAT-siRNAs; and the fourth group
was co-injected with 2 lL LV-DAT together with 2 lL of a mix of the
three LV-DAT-siRNAs.
Experiment 2: effects of c-synuclein on cocaine-induced locomotor
activity
Four groups of animals (n ¼ 8) were prepared: one group was
stereotaxically injected with 2 lL of LV-GFP (controls); a second
group was injected with 2 lL of LV-cSyn; a third group was injected
with 2 lL of a mix of all three LV-cSyn-siRNAs; and the fourth group
was injected with 2 lL LV-cSyn together with 2 lL of a mix of the
three LV-cSyn-siRNAs.
Experiment 3: effects of DAT and c-synuclein on cocaine-induced
locomotor activity
Four groups of animals (n ¼ 8) were prepared: one group was
stereotaxically injected with 2 lL of LV-GFP (controls); one group
was stereotaxically injected with 2 lL of LV-DAT; a third group was
injected with 2 lL of a mix of all three LV-cSyn; and the fourth group
was injected with 2 lL LV-DAT together with 2 lL of the LV-cSyn.
After a recovering period of 7–12 days, locomotor activity was
monitored in daily sessions over 3 · 5 days in 43.2 · 43.2-cm MED-
OFA-RS cages (MED Associates, USA) during the dark cycle,
according to previously published procedures (Bahi et al., 2004a,b).
Animals were fed without doxycycline for 5 days (Session A), then fed
doxycycline for 5 days (Session B), and ﬁnally fed without doxycycline
for 5 days (Session C). Prior to each locomotor activity measurement,
the animal was injected with 0.9% saline solution, placed into the
activity-monitoring cage for a 15 min baseline. After this 15-min
period, the session automatically paused for a few seconds and, during
this interval, each subject received cocaine-HCl (Sigma, 15 mg ⁄ kg,
i.p.) and was then placed back into the locomotor activity-monitoring
cage for a further 60 min. At the end of the third session (Session C),
one half of the animals were killed by decapitation. The other half was
switched back on doxycycline for 48 h then killed. During this switch
period, animals were still daily administered cocaine and, as for the
other group, were killed 24 h after the last cocaine injection. Brains
were used either for immunocytochemistry or qRT-PCR.
In vivo assays of c-synuclein
To assess the efﬁciency of lentiviruses-mediated expression of
c-synuclein and DAT in vivo, brains, after death, were either frozen
for immunohistochemistry analysis or dissected out and homogenized
for protein or qRT-PCR analysis. For molecular analysis, NAc,
striatum and ventral tegmental area (VTA) regions were isolated and
tissues were used for RNA extraction using TRIzol Reagent (Invitro-
gen, Basel, Switzerland) or for protein extraction.
Statistical analyses
Two-way anova was used to compare both lentiviral and drug
treatment in the presence or absence of doxycycline, using GraphPad
PRISM (V3.0, GraphPad, San Diego, CA, USA). For locomotor
activity, two-way anova was used with time as the within-subject
factors and lentiviral treatment as the between-subject factors,
followed by Bonferroni post hoc tests. For self-administration and
real-time PCR analysis, two-way anova were used with drug
treatment (water vs doxycycline) as the within-subject factors and
lentiviral treatment as the between-subject factors, followed by
Bonferroni post hoc tests.
Results
Cocaine-mediated behavioural changes upon DAT
or c-synuclein expression
Lentiviruses used in this study were prepared and tested in vitro for
assessing expression or silencing of DAT and c-synuclein, in different
combinations prior to in vivo assays (see Supplementary material,
Appendix S1, Figs S1 and S2, and Table S1).
Experiment 1: effects of DAT on cocaine-induced locomotor activity
To test the effects of DAT expression changes in the NAc on cocaine-
induced locomotor activity, four groups of animals (n ¼ 8) were used.
A ﬁrst group of animals, infected with the LV-GFP, served as a control
group and expressed the GFP in the NAc in a doxycycline-regulated
way. Previous work clearly established that GFP-overexpression in the
NAc has no signiﬁcant effect on locomotor activity, compared with
naı¨ve animals (Bahi et al., 2004a,b). One week after surgery, animals
were fed 5% sucrose, chronic cocaine delivery was started and
locomotor activity was monitored during ﬁve consecutive days.
Animals overexpressing GFP displayed a signiﬁcant induction of
locomotor activity upon cocaine injection, with a peak at 4300 counts
(Fig. 1 upper panel, Session A. See also supplementary Fig. S3). At
the end of this 5-day session, animals were fed doxycycline (0.02% in
5% sucrose) to switch off ectopic gene expression. For 2 days (switch
period), animals received i.p. cocaine injection but locomotor activity
was not monitored, in order to achieve a full, doxycycline-mediated
switch off of ectopic gene expression. Thereafter, the locomotor
activity was monitored for 5 days on animals still fed doxycycline
(Session B). Under these conditions, cocaine-mediated locomotor
activity from these GFP-overexpressing animals remained unchanged,
with a peak at 4700 counts (Fig. 1 upper panel, Session B). After this
5-day session, animals were again submitted to a 2-day switch period
during which animals were fed only 5% sucrose (no doxycycline).
Thereafter, locomotor activity was monitored for ﬁve consecutive days
on animals still fed without doxycycline, and chronically cocaine
injected. During this last period (Session C), cocaine-induced
locomotor activity also remained unchanged, with a peak at 4800
counts (Fig. 1 upper panel, Session C).
The second group of animals was infected with doxycycline-
regulatable LV-DAT in the NAc. In the absence of doxycycline
(Session A), overexpression of DAT induced a signiﬁcant decrease in
locomotor activity compared with the control group (LV-GFP-treated











F3,240 ¼ 550.8), whereas under the doxycycline regimen, these same
LV-DAT-treated animals demonstrated a locomotor activity very
similar to controls (LV-GFP-injected animals) under the same
conditions, with a peak at 4700 counts (Fig. 1 upper panels;
P > 0.05, F3,240 ¼ 210.9). After 5 days of the doxycycline regimen,
doxycycline was removed, enabling re-expression of lentivirus-
mediated DAT expression in the NAc, and after a 2-day switch period
locomotor activity was monitored for 5 days (Session C): under these
conditions the LV-DAT-infected group again demonstrated a signif-
icant reduction in locomotor activity, compared with the control group,
Fig. 1. In vivo effects of dopamine transporter (DAT) and c-synuclein expression in the NAc on cocaine-induced locomotor activity. Values represent
means ± SEM of distance travelled over 5 days of measurement (n ¼ 8 animals). One week after surgery, after a recovering period of 7–12 days, chronic cocaine
delivery was started and locomotor activity was monitored in daily sessions over 3 · 5 days in 43.2 · 43.2 cm MED-OFA-RS cages (MED Associates, USA)
during the dark cycle (see Materials and methods). The paradigm comprises an i.p. saline injection prior to the habituation period of 15 min, and an i.p. cocaine
injection (15 mg ⁄ kg) followed by 1 h recording. Over 5 days, animals were fed without doxycycline (Session A), yielding to full expression of DAT or c-synuclein
in the targeted brain area. This was followed by a switch period of 2 days during which animals were fed doxycycline and cocaine injected but not recorded for
locomotor activity. During Session B, animals were fed doxycycline in order to switch back ectopic gene expression. At the end of Session B and during two
consecutive days animals were submitted again to a switch period during which doxycycline was removed. This was followed by a 5-day period without doxycycline
(Session C, regimen identical to Session A). Overexpression of DAT in the NAc (upper panels) induced a signiﬁcant decrease on cocaine-induced locomotor activity
that could be abolished by doxycycline treatment. Silencing of DAT (second row of panels) lead to an increase of cocaine-induced locomotor activity. By contrast,
c-synuclein overexpression in the NAc (third row of panels) has no consequences in cocaine-induced locomotor activity, whereas silencing of c-synuclein (lower
panels) lead to a signiﬁcant decrease in locomotor activity compared with the control group. $$$P < 0.001, as compared with LV-green ﬂuorescent protein












with a peak at 2700 counts as in Session A (Fig. 1 upper panels;
P < 0.001, F3,240 ¼ 828.9; see also supplementary Fig. S3).
The third group of animals was co-injected with the regulatable
LV-DAT together with non-regulatable LV-DAT-siRNAs. In the absence
of doxycycline (Session A), a signiﬁcant increase in locomotor activity
was observed, compared with the control group (LV-GFP-treated
animals), with a peak at 5900 counts (Fig. 1 second row; P < 0.001;
F3,240 ¼ 550.8). Under the doxycycline regimen, only ectopic expres-
sion of DATwas turned off, as the LV-DAT-siRNAs are not doxycycline
regulatable and thus inhibit endogenousDATexpression; this resulted in
a further increase in cocaine-mediated locomotor activity, with a peak at
6400 counts. (Fig. 1 second row; P < 0.001; F3,240 ¼ 210.9). Removal
of doxycycline in Session C induced an increase in locomotor activity,
with a peak at 7000 counts (Fig. 1 second row; P < 0.001;
F3,240 ¼ 828.9; see also supplementary Fig. S3).
The fourth group of animals was injected with non-regulatable
LV-DAT-siRNAs, in order to knock-down endogenous expression of
the DAT in the NAc. In Session A, a dramatic increase in locomotor
activity after cocaine injection was observed, as a result of knock-
down of endogenous DAT, with a peak at 7100 counts (Fig. 1 second
row; P < 0.001; F3,240 ¼ 550.8), which was not affected by doxycy-
cline. In Sessions B and C, peaks at 7700 counts and 8600 counts were
observed (Fig. 1 second row; P < 0.001; F3,240 ¼ 210.9 and
P < 0.001; F3,240 ¼ 828.9, respectively).
Experiment 2: effects of c-synuclein on cocaine-induced locomotor
activity
The effects of c-synuclein expression on cocaine-induced locomotor
activity were tested similarly in four groups of animals (n ¼ 8). A ﬁrst
group of animals (control), injected with doxycycline-regulatable
LV-GFP in the NAc, demonstrated a cocaine-induced locomotor
activity unaffected by doxycycline regimen, with peaks at 4100
counts, 4300 counts and 4400 counts in Sessions A–C, respectively
(Fig. 1 third row and supplementary Fig. S3).
The second group, injected with LV-cSyn in the NAc, locally
overexpressing c-synuclein, displayed locomotor activity similar to
the control group during Session A, with a peak at 4700 counts (Fig. 1
third row; P > 0.05; F4,300 ¼ 111.7). Upon the doxycycline regimen
(Session B), leading to switch off of ectopic c-synuclein expression,
cocaine-induced locomotor activity was not signiﬁcantly different and
very similar to the control group, with a peak at 4700 counts (Fig. 1
third row; P > 0.05; F4,300 ¼ 151.1). Animals were then switched
back to the doxycycline-free regimen (Session C), leading again to
overexpression of c-synuclein in the NAc: under these conditions
again, locomotor activity was similar to the control group (Fig. 1 third
row; P > 0.05; F4,300 ¼ 117.8; see also supplementary Fig. S3).
The third group of animals was co-injected with a doxycycline-
regulatable LV-cSyn together with non-regulatable LV-cSyn-siRNAs.
In the absence of doxycycline (Session A), cocaine-induced locomotor
activity was strongly reduced and signiﬁcantly lower than the control
group (Fig. 1 last row; P < 0.001; F4,300 ¼ 111.7; see also supple-
mentary Fig. S3). Switch to the doxycycline regimen (Session B)
switches off ectopic c-synuclein overexpression, maintaining silencing
of endogenous c-synuclein; under these conditions, rats still demon-
strated a signiﬁcant decrease in locomotor activity, compared with
GFP-infected animals (Fig. 1 last row; P < 0.001; F4,300 ¼ 151.1),
which remained unaffected upon removal of doxycycline (Session C;
Fig. 1 last row; P > 0.05; F4,300 ¼ 117.8).
A fourth group of animals was injected only with non-regulatable
LV-cSyn-siRNAs, in order to knock-down the expression of endog-
enous c-synuclein in the NAc. During Session A, animals displayed a
signiﬁcant reduction of cocaine-induced locomotor activity, compared
with the control group, with a peak at 2200 counts (Fig. 1 last row;
P < 0.001; F4,300 ¼ 111.7). Despite the fact that these lentiviruses
were not doxycycline regulatable, animals were nevertheless submit-
ted to the doxycycline regimen, for effective comparison between
groups. Doxycycline switch did not signiﬁcantly affect locomotor
activity and, during Session B, these rats still showed a signiﬁcant
decrease in locomotor activity, as compared with LV-GFP-treated
animals (Fig. 1 last row; P < 0.001; F4,300 ¼ 151.1). This was
unmodiﬁed upon removal of doxycycline (Session C; Fig. 1 last row;
P > 0.05; F4,300 ¼ 117.8; see also supplementary Fig. S3). These
results demonstrated that local changes in c-synuclein expression may
affect cocaine-induced locomotor activity. In order to establish
whether these changes would synergize or antagonize those observed
upon DAT manipulation, the impact of co-injection of LV-DAT and
LV-cSyn in the NAc on cocaine-induced locomotor activity was
investigated.
Experiment 3: effects of DAT and c-synuclein on cocaine-induced
locomotor activity
To elucidate putative interactions between DAT and c-synuclein and
their consequences on behaviour, four groups of animals (n ¼ 8) were
used. The control group, injected with LV-GFP in the NAc, displayed
doxycycline-independent cocaine-induced locomotor activity, with a
peak at 4400 counts during all three sessions (Fig. 2 upper and middle
rows).
The second group of animals was injected with LV-DAT in the NAc,
leading to doxycycline-regulatable overexpression of DAT in this
brain area. Animals fed only 5% sucrose (Session A) displayed a
signiﬁcant decrease in cocaine-induced locomotor activity, with a peak
at 2900 counts (Fig. 2 upper row; P < 0.001; F3,240 ¼ 227.1). The
doxycycline regimen, that switches off ectopic DAT expression,
induced normal locomotor activity, comparable to that recorded in the
control group (Fig. 2, upper row; P > 0.05; F3,240 ¼ 92.7). Removal
of doxycycline for these same animals, thus re-instating DAT
overexpression in the NAc, restored the initial signiﬁcant decrease
in locomotor activity, as compared with the control group, with a peak
at 3000 counts (Fig. 2, upper row; P < 0.01; F3,240 ¼ 441.1; see also
supplementary Fig. S2). These results were totally similar to those
obtained in the previous experiments (Fig. 1), conﬁrming the strong
impact (hypolocomotion) of DAT overexpression on cocaine-induced
locomotor activity.
The third group was injected with the LV-cSyn in the NAc,
submitted to the same regimen as described above. As discussed
previously (Fig. 1), the induction of ectopic expression of c-synuclein
in this area had apparently no consequences on cocaine-induced
locomotor activity (Sessions A–C), as no differences were detected on
LV-cSyn-treated animals compared with LV-GFP-injected rats (Fig. 2;
middle rows, P > 0.05).
The fourth group of animals was co-injected with LV-DAT and
LV-cSyn in the NAc. Surprisingly, locomotor activity recorded during
Session A was strongly increased, compared with the control group,
with a peak at 5900 counts (Fig. 2, lower rows; P > 0.001;
F3,240 ¼ 277.1). Thus, DAT, which reduces locomotion, enables
c-synuclein, which has no effect alone, to increase locomotion.
Despite its oddity, these data could be fully reproduced in another
laboratory (data not shown). Doxycycline treatment (Session B) totally
abolished the observed hyperlocomotion, and the locomotor activity
returned to a basal level comparable to that observed in the LV-GFP
group, with a peak at 5300 counts (Fig. 2, lower rows; P > 0.05;











overexpression of DAT and c-synuclein proteins that reinstated
hyperlocomotor activity back to its initial levels, with a peak at
6500 counts after cocaine injection (Fig. 2, lower rows; P < 0.001;
F3,240 ¼ 92.7; see also supplementary Fig. S3). These data clearly
suggest that this cocaine-induced hyperlocomotion, mediated by
overexpression of both DAT and c-synuclein together, could be caused
by (direct or indirect) interaction.
mRNA expression in vivo
DAT mRNA expression in Experiment 1
At the end of behavioural analyses, half of the animals from each
groups were killed, the second half of the animals was fed doxycycline
for 48 h (turning off lentivirus-mediated gene overexpression in the
NAc), then killed. After killing, brains were removed, NAc tissues
were dissected out and used for total RNA extraction, Western blots
analysis or immunohistochemistry analysis After reverse transcription,
mRNA expression levels were measured by means of qRT-PCR. Data
are shown in Fig. 3A–D.
When animals had been injected with LV-GFP, DAT mRNA
expression was detected with a ratio of 1.1. Animals from this group
that were switched to doxycycline displayed the same ratio of DAT
expression. The ratios of cyclophilin F and GAPDH mRNA remained
unchanged over cocaine-treated control animals in both cases (not
shown).
When animals had been injected with LV-DAT alone, strong
induction of DAT mRNA expression was observed in the absence of
Fig. 2. In vivo effects of dopamine transporter (DAT) and c-synuclein overexpression in the NAc on cocaine-induced locomotor activity. Values represent
means ± SEM distance travelled over 5 days of measurement (n ¼ 8 animals). Four groups of animals were injected bilaterally in the NAc with either LV-DAT
alone, LV-cSyn alone, LV-GFP alone or LV-DAT together with LV-cSyn. One week after surgery, cocaine-induced locomotor activity was measured under a regimen
identical to Fig. 1. During Sessions A and C animals were fed without doxycycline yielding to full expression of DAT and c-synuclein, whereas during Session B
animals were fed with doxycycline and ectopic genes expression is suppressed. Overexpression of DAT in the NAc induced a decrease in cocaine-induced locomotor
activity (upper panels), whereas overexpression of c-synuclein alone in the same brain area has no consequences on locomotor activity (middle panels). Note that co-
expression of DAT and c-synuclein in the NAc (lower panels) leads to a signiﬁcant increase in cocaine-induced locomotor activity; these changes could be totally
abolished by doxycycline treatment. $$$P < 0.001 compared with LV-green ﬂuorescent protein (GFP)-injected rats. +++P < 0.001 compared with LV-DAT-injected











doxycycline, with a ratio of 5.9 compared with LV-GFP-treated
controls (Fig. 3A; P < 0.001; F7,48 ¼ 26.9). This expression level
dropped to 1.2-fold upon the doxycycline regimen, equivalent to the
ratio observed for GFP-treated animals. GAPDH mRNA expression
was not affected, and ratios of 1 and 0.9 (in the absence or presence of
doxycycline, respectively) were found, similar to those observed in the
previous group (not shown).
When animals had been injected with LV-DAT together with a mix
of LV-DAT-siRNAs a decrease of DAT expression was found in the
absence of doxycycline, resulting in a ratio of 1.8 (P < 0.01;
F7,48 ¼ 26.9). With doxycycline treatment, complete inhibition of
DAT was found, with ratios 0.2 (Fig. 3A; P < 0.01; F7,48 ¼ 26.9).
Indeed, doxycycline blocks exogenous, lentivirus-mediated DAT
overexpression ) but not endogenously expressed DAT ) while
silencers also block endogenous DAT. Under these conditions, the
other targets (GAPDH, etc.) were not modiﬁed, indicating that
LV-DAT-siRNAs had no effects on their expression levels.
Finally, when animals have been injected with LV-DAT-siRNAs
only (without LV-DAT), the DAT mRNA expression level dropped to
0.5 and even to 0.15 with doxycycline (Fig. 3A; P < 0.01),
corresponding to full silencing of endogenous DAT mRNA expres-
sion, whereas GAPDH mRNA was not modiﬁed.
Synuclein mRNA expression in Experiment 2
Animals injected with LV-GFP displayed c-synuclein mRNA expres-
sion with a ratio of 1.04 in the absence of doxycycline. When switched
to doxycycline the same ratio (1.1) of c-synuclein mRNA expression
was found. No changes in GAPDH ratios were found in this group in
both cases (Fig. 3B).
Animals injected with LV-cSyn displayed a strong increase of
c-synuclein mRNA expression, with a ratio of 6.9 in the absence
of doxycycline, whereas in the presence of doxycycline this ratio
dropped to 1.2 (Fig. 3B; P < 0.001; F7,48 ¼ 8.9). Thus, the lack of
Fig. 3. mRNA quantiﬁcation of in vivo gene expression from NAc-infected animals. Quantiﬁcations by means of qRT-PCR. At the end of the behavioural tests,
animals were killed and NAc was dissected out. Total RNAwas extracted using the Trizol method, cDNAwas prepared and transcripts levels were quantiﬁed using
the real-time PCR method with speciﬁc primers. Quantitative mRNA levels were normalized against cyclophilin F. GAPDH mRNA was also analysed as an
endogenous control. Data represent means ± SEM. (A) In vivo expression of dopamine transporter (DAT) mRNA from NAc of LV-DAT- and ⁄ or LV-DAT-siRNAs-
infected rats. ***P < 0.001, **P < 0.01 compared with LV-green ﬂuorescent protein (GFP)-injected rats. (B) In vivo expression of c-synuclein mRNA from NAc
of LV-cSyn- and ⁄ or LV-siRNAs-cSyn-infected rats. ***P < 0.001, *P < 0.05 compared with LV-GFP-injected rats. (C) In vivo expression of DAT mRNA from
NAc of rats injected with LV-cSyn, LV-DAT, LV-DAT + LV-cSyn or LV-GFP. ***P < 0.001, **P < 0.01, *P < 0.05 compared with LV-GFP-injected rats.
(D) In vivo expression of c-synuclein mRNA from NAc of rats injected with LV-cSyn, LV-DAT, LV-DAT + LV-cSyn or LV-GFP. ***P < 0.001, **P < 0.01,











behavioural changes in LV-cSyn-injected rats was not due to a trouble
of LV-cSyn expression.
Animals co-injected with LV-cSyn and LV-cSyn-siRNAs displayed
expression levels of c-synuclein transcripts similar to those found in
control groups, with a ratio of 1.5 in the absence of doxycycline
(Fig. 3B; P > 0.05; F7,48 ¼ 8.9). Under the doxycycline regimen, a
signiﬁcant decrease in c-synuclein transcripts level was observed, with
a ratio of 0.6 (Fig. 3B; P < 0.05; F7,48 ¼ 8.9).
Animals injected with LV-cSyn-siRNAs alone displayed an inhi-
bition of c-synuclein expression with ratios of 0.5 and 0.6 in the
presence or absence of doxycycline, respectively (Fig. 3B; P < 0.05;
F7,48 ¼ 8.9). In all these groups no changes in GAPDH transcripts
levels were observed.
mRNA expression in Experiment 3
In this experiment, in LV-GFP-injected animals, DAT expression was
not affected by doxycycline regimen and showed a stable ratio of 0.9
under all conditions (Fig. 3C). Animals injected with LV-DAT in the
NAc displayed a high increase of DAT mRNA expression in
doxycycline-free regimen, with a ratio of 9.4 (Fig. 3C; P < 0.001;
F7,48 ¼ 105.5), which returned to a basal level comparable to that
observed in the control group in the presence of doxycycline, with a
ratio of 1.3 (Fig. 3C; P > 0.05; F7,48 ¼ 105.5). Animals co-injected
with LV-DAT and LV-cSyn displayed higher levels of DAT expression
in the absence of doxycycline, with a ratio of 11.1 (Fig. 3C;
P < 0.001; F7,48 ¼ 105.5) and a ratio of 0.6 in the presence of
doxycycline, signiﬁcantly lower than that observed in the control
group (Fig. 3C; P < 0.05; F7,48 ¼ 105.5).
Under these conditions, c-synuclein mRNA expression was signif-
icantly increased in animals injected with LV-cSyn (Fig. 3B) or in the
group of animals co-injected with LV-DAT and LV-cSyn (Fig. 3D),
with ratios of 11.2 and 9.2, respectively, in the absence of doxycycline
(P < 0.001; F7,48 ¼ 105.5), and a ratio of 1.5 in the co-injected group
under the doxycycline regimen (Fig. 3D; P > 0.05; F7,48 ¼ 105.5),
similar to that observed in the control group. Interestingly, however,
under the doxycycline regimen the LV-cSyn group displayed a ratio of
3.2, still signiﬁcantly higher than that observed for the control LV-GFP
group (Fig. 3D; P < 0.05; F7,48 ¼ 105.5).
Protein expression in vivo
Protein expression was assessed after behavioural analysis on animals
from all groups described above. After death, brains were dissected
out, and the NAcs were used for Western blot analysis.
LV-cSyn injection in the NAc resulted in a signiﬁcant increase of
c-synuclein protein expression in that region, compared with LV-GFP-
injected rats (Fig. 4A and C; P < 0.001; F5,24 ¼ 37.4). Under the
doxycycline regimen, this increase was abolished and c-synuclein
protein levels returned back to basal levels observed in the control
group (Fig. 4B; P > 0.05; F5,24 ¼ 37.4). Furthermore, injection of LV-
cSyn-siRNAs in the NAc resulted in drastic c-synuclein protein
knock-down under all regimens, with ratios signiﬁcantly lower than
those observed for LV-GFP-injected rats (Fig. 4A–C; P < 0.01;
F5,24 ¼ 37.4). Co-injection of LV-cSyn and LV-cSyn-siRNAs pro-
duced no signiﬁcant differences in c-synuclein protein levels under all
regimens, as compared with the control, LV-GFP-injected group
(Fig. 4A–C; P > 0.05; F5,24 ¼ 37.4).
When rats were injected with LV-DAT in the NAc, a signiﬁcant
increase of DAT protein levels was found in that region in the absence
of doxycycline [Fig. 4A (right panel) and D; P < 0.001;
F5,24 ¼ 26.8]. In the presence of doxycycline, DAT expression was
strongly reduced, and protein levels were similar to those observed in
the control (LV-GFP-treated) group [Fig. 4B (right panel) and D;
P > 0.05; F5,24 ¼ 26.8]. Animals injected with LV-DAT-siRNAs
displayed a strong decrease of DAT protein expression under all
doxycycline regimens, as compared with the control group (Fig. 4A, B
and D; P < 0.001; F5,24 ¼ 26.8). Interestingly, no signiﬁcant effects
on DAT protein expression were found when LV-DAT has been
co-injected with LV-DAT-siRNAs (Fig. 4D).
Co-injection of LV-DAT and LV-cSyn in the NAc led to strong
induction of expression of both proteins in that region. In this
experiment, animals displayed DAT and c-synuclein protein levels
signiﬁcantly different to LV-GFP-injected rats (Fig. 4A; P < 0.001).
Doxycycline treatment of rats from this co-injected group resulted in a
decrease of c-synuclein protein expression that returned to basal
levels, whereas the expression of DAT protein showed a weaker
decrease in expression but its level was still signiﬁcantly different
compared with the control group (Fig. 4A and E; P < 0.05).
Immunohistochemistry analysis
Immunohistochemistry was performed on brains from animals treated
with LV-cSyn together with LV-DAT (Fig. 5). Animals treated with
LV-cSyn and LV-DAT display a very strong overexpression of both
proteins in the NAc. Low-magniﬁcation immunolabelled pictures
demonstrate full infection of the entire NAc by both lentiviruses
(Fig. 5A). In the NAc the expression of c-synuclein (Fig. 5A red, left)
and DAT (Fig. 5A brown, right) covers the entire zone of interest, but
expression is limited in that zone, demonstrating again the low
capacity of diffusion of lentiviruses within the zone of injection.
Clearly lentiviruses do not diffuse into other parts of the brain away
from the zone of injection. This enables to drive the regulatable
expression of the genes of interest (c-synuclein and DAT) without any
spreading into other regions, which might compromise interpretation
of observed behavioural changes. High-magniﬁcation views of gene
expression in the NAc show that overexpression of c-synuclein and
DAT is almost exclusively neuronal within the NAc, and demonstrate
the high expression of c-synuclein (red, left) and DAT (green, middle)
proteins and their co-localization within neurites (Fig. 5B, upper
panels) as well as at the cell bodies (Fig. 5B, lower panels). The
subcellular co-localization of c-synuclein and DAT protein expression
could explain the synergic effects found in the locomotor activity
analysis.
Expression in the VTA
In this study lentiviruses have been injected in the NAc and changes in
gene expression are observed in this brain region (Figs 3–5).
Lentivirus infection is very limited to the targeted brain area
(Fig. 5). However, retrotransport of virus from infected accumbal
dopaminergic neurons back to the VTA is observed, and ectopic,
doxycycline-regulatable, c-synuclein and DAT gene expression (or
silencing) in the VTA is found in the different groups, as shown by
immunocytochemistry and Western blot analysis from tissue of that
region (supplementary Fig. S4).
Discussion
Our results demonstrate that local changes in c-synuclein expression
may affect cocaine-induced locomotor activity. Overexpression of c-
synuclein in the NAc alone had no effect, while local silencing lead to











decrease compared with controls). Surprisingly, co-injection of
lentiviruses expressing DAT and c-synuclein ) leading to overex-
pression of both proteins in the NAc ) resulted in a strong increase in
cocaine-induced rat locomotor activity (52% increase compared with
controls). This increase in locomotor activity was abolished upon
locally silencing these genes. Thus, c-synuclein, which by itself has no
effect alone, enables DAT, which reduces locomotion, to increase
locomotion; despite its oddity, these data could be fully reproduced
(including qRT-PCR and Western blot analysis) in another laboratory
under the same paradigms and also under different paradigms, e.g.
self-administration (collaboration with Dr V. Deroche-Gamonet, CRI
U862, Bordeaux, unpublished). This suggests a synergistic role of
both proteins, possibly mediated through a direct interaction. By
contrast previous works have shown that overexpression of
a-synuclein in the NAc induces a 45% increase in locomotor activity,
while local silencing of a-synuclein in the NAc resulted in signiﬁcant
hypolocomotion activity and a decrease in self-administration (Boyer
& Dreyer, 2007).
Together these data demonstrate that both a- and c-synuclein
modulate cocaine-induced behavioural effects, in different ways but
probably by interaction with DAT (Lavedan, 1998; George, 2001). It
has been well established that synuclein activity helps regulate the
dopaminergic system (Brenz-Verca et al., 2003; Ferguson, 2003;
Wersinger & Sidhu, 2003; Wersinger et al., 2003a, b). a-Synuclein,
serving as a chaperone protein, is involved in the regulation of the
activity of DAT and of tyrosine hydroxylase, which controls the level
of monoamine neurotransmitters in the brain (Perez et al., 2002;
Liang et al., 2003; Mash et al., 2003). Qin et al. (2005) demonstrated
concomitant regulation of a-synuclein and DAT binding and function
in human striatal synaptic terminals isolated from cocaine abusers,
indicating that overexpression of a-synuclein may play a role in
cocaine-induced plasticity and regulation of dopamine synaptic tone.
The DAT represents the major presynaptic component involved in
terminating dopaminergic neurotransmission through facilitating the
reuptake of synaptic dopamine (Horn, 1990; Chen & Reith, 2000),
and thus may bolster the production of reactive free radical
Fig. 4. Western blot analysis of dopamine transporter (DAT) and c-synuclein protein expression in the NAc of infected animals. Western blots from gels loaded
with 20 lg protein ⁄ lane were analysed for either DAT or c-synuclein expression, and reprobed with b-actin antibody to compare DAT or c-synuclein expression in
lentivirus-infected NAc of rats. (A) Immunoblots of DAT and c-synuclein expression from NAc of animals in doxycycline-free conditions. (B) Immunoblots of
DAT and c-synuclein expression from NAc of animals under doxycycline treatment. c-Synuclein and DAT signals were estimated using multianalyst software and
normalized against the b-actin signal (see Materials and methods for details). Data represent means ± SEM. (C) In vivoc-synuclein protein levels quantiﬁcation.
***P < 0.001, **P < 0.01: semiquantitative c-synuclein protein quantiﬁcation vs c-synuclein quantiﬁcation detected from LV-green ﬂuorescent protein (GFP)-
injected rats. (D) In vivo DAT protein levels quantiﬁcation. ***P < 0.001, **P < 0.01: semiquantitative DAT protein quantiﬁcation vs DAT quantiﬁcation detected
from LV-GFP-injected rats. (E) In vivoc-synuclein and DAT protein levels quantiﬁcation in the group co-infected with LV-DAT together with LV-cSyn.











metabolites that would induce neurotoxicity of dopaminergic cells.
Therefore, regulation of DAT function plays a critical role in the
aetiology of dopamine-related neurological diseases (such as Parkin-
son’s disease).
DAT is expressed at presynaptic dopaminergic terminals in the NAc
and produced by dopaminergic neurons projecting from the VTA. In
addition, very low levels of DAT mRNA in the NAc have been
described in naı¨ve animals (Maggos et al., 1998), in agreement with
our observations. Under our experimental conditions, however, we
cannot rule out the possibility that Glu- and c-aminobutyric acid
(GABA)-ergic neurons also take up the virus and that these neurons
artiﬁcially express DAT in the NAc, whereas under normal conditions
DAT would only be expressed by dopaminergic neurons in this brain
area. Nevertheless, this does not alter our observations that overex-
pression of DAT in the NAc, by modifying synaptic levels of
dopamine, affects cocaine-induced behaviour. Our data indicate that
locally silencing a- or c-synuclein induces distinct behavioural
changes in cocaine-mediated locomotor activity. In contrast to
a-synuclein, c-synuclein (or parkin) is an E3 ligase that mediates
the ubiquitination of proteins, targeting them for degradation, and
plays a protective role against dopamine-induced oxidative stress and
apoptosis and against a-synuclein toxicity (Petrucelli et al., 2002;
Oluwatosin-Chigbu et al., 2003; Jiang et al., 2004; LoBianco et al.,
2002; Yamada et al., 2005). In addition, c-synuclein can affect
a-synuclein-mediated toxicity (Choi et al., 2001; Chung et al., 2001;
Shimura et al., 2001; Petrucelli et al., 2002; Kim et al., 2002),
suggesting functional cross-talk between c-synuclein and a-synuclein.
In cocaine paradigms, induction of both a- and c-synuclein has been
Fig. 5. Immunohistochemistry of c-synuclein and dopamine transporter (DAT) expression in the NAc. Immunohistochemistry was performed after in vivo delivery
of LV-cSyn (2 lL) combined with LV-DAT (2 lL) Lentiviruses were injected into the NAc according to the coordinates described in the Materials and methods.
Animals used for behavioural analysis were fed either 5% sucrose or 5% sucrose ⁄ 0.02% doxycycline (see text for details). Animals were killed at the end of
behavioural analyses; brains were dissected out and processed for immunohistochemistry (see Materials and methods). (A) Low-magniﬁcation expression of
c-synuclein (left) and DAT (right) in the NAc. Sections were double-labelled using c-synuclein (red) or DAT antibody (brown), and revealed by immunoﬂuorescence
(Texas-red for cSyn) and HRP-DAB (brown, for DAT). Pictures were taken at 2.5 · magnitude. (B) High-magniﬁcation expression of c-synuclein (left) and DAT
(middle) and merge (right) shows co-localization of c-synuclein and DAT expression. Brain sections from animals fed 5% sucrose were labelled using antibodies
against c-synuclein (red) and DAT (green), and were visualized by ﬂuorescence microscopy at 100 · magnitude. Lentiviral overexpression of c-synuclein and DAT
shows an increase in c-synuclein expression (red) that is co-localized with the DAT labelling (green). The ﬁrst row demonstrates the co-localization (merge, yellow)











observed (Brenz-Verca et al., 2003); however, to our knowledge
ﬁbrillation of synucleins in cocaine-treated animals has not been
observed. From this, one may imply that cocaine induces a-synuclein
for promoting DAT-trafﬁcking, but this is balanced by concomitant
c-synuclein expression.
c-Synuclein mediates both classical K48 ubiquitination of
substrate proteins (that leads to proteasomal degradation), and also
non-classical K63 polyubiquitination (Lim et al., 2005), which
diverts proteins away from proteasomal degradation and may have
roles in DNA repair, translational regulation and endocytosis
(Pickart, 2000). Ubiquitination may play a role in protein trafﬁcking
(Aguilar & Wendland, 2003; Hicke & Dunn, 2003) and in targeting
proteins to endosomes from the plasma membrane (Hicke, 2001).
As a matter of fact, a major mechanism in regulating DAT function
is through DAT trafﬁcking. The primary mechanism whereby the
uptake velocity of the presynaptic DAT is decreased or increased is
via the rapid internalization of cell surface DAT into various
intracellular compartments or mobilization of DAT to the cell
surface from these pools (Pristupa et al., 1998; Daniels & Amara,
1999; Melikian & Buckley, 1999). The a-synuclein ⁄DAT complex
decreases Km of DAT for dopamine and facilitates the plasma
membrane clustering of the DAT, thereby accelerating cellular
dopamine uptake (Wersinger & Sidhu, 2003). Enhancement of [3H]
dopamine uptake by a-synuclein has been described, as a conse-
quence of increased DAT found at the plasma membrane (George,
2001; Pinhasov et al., 2005). We have shown that an increase in
a-synuclein expression strongly correlates with behavioural changes
observed under different drug administration paradigms (Boyer &
Dreyer, 2007). Local overexpression of a-synuclein in the NAc
rapidly induces increased locomotor response to cocaine and
increased self-administration of the drug, whereas selective knock-
down of a-synuclein in the NAc strongly affects behaviour (Boyer
& Dreyer, 2007). It has been shown that c-synuclein blocks the
a-synuclein-induced enhancement of DAT uptake by decreasing the
DAT membrane expression (Moszczynska et al., 2007). This is
mediated through a direct interaction between the DAT and
c-synuclein, which disrupts the interaction between the DAT and
a-synuclein (Moszczynska et al., 2007). By disrupting the
DAT ⁄ a-synuclein interaction, c-synuclein not only reduces the level
of dopamine reuptake, but consequentially mitigates the toxicity of
exogenous dopamine in the presence of a-synuclein. Moreover,
dopamine has been reported to lead to the inactivation of
c-synuclein (LaVoie et al., 2005), therefore having increased DAT
expression can lead to increased intracellular dopamine levels and
subsequent inactivation of c-synuclein.
Dopamine (also l-DOPA and other catecholamines) may inhibit
ﬁbrillation of a-synuclein and amyloid b-peptide; their oxidation
products are potent inhibitors of a-synuclein ﬁbrillation and may
dissolve preformed ﬁbrils (Conway et al., 2001; Li et al., 2002). The
inhibitory activity of dopamine was attributed to the formation of
covalent adducts between the o-quinone derivative of dopamine and
a-synuclein, causing an accumulation of the covalently modiﬁed
protoﬁbrils that are unable to ﬁbrillate (Conway et al., 2001; Cappai
et al., 2005). Both a- and c-synucleins may form ﬁbrils (Uversky
et al., 2002), although this has not been observed in cocaine-treated
animals or human patients. The addition of either c-synuclein in a
1 : 1 molar ratio to a-synuclein solution substantially increases the
duration of the lag-time and reduces the elongation rate of a-synuclein
ﬁbrillation (Uversky et al., 2002). Fibrillation is completely inhibited
at a 4 : 1 molar excess of c-synuclein over a-synuclein (Hashimoto
et al., 2001; Uversky et al., 2002), suggesting that c-synucleins may
act as a regulator of a-synuclein ﬁbrillation in vivo, potentially acting
as chaperone (Uversky et al., 2002). Further molecular studies will be
needed to establish the very function of the two synucleins in cocaine
paradigms, in relation to DAT expression.
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In vitro assay of lentivirus-mediated J-synuclein expression in HEK 293T cells: J-
Synuclein was cloned into a tetracycline-regulatable Lentivirus system (see Methods). The 
efficiency to LV-JSyn to mediated J-synuclein mRNA overexpression was check in vitro 
(see methods). HEK 293 T cells were infected with different concentrations of virus (1, 2, 4 
and 8l) and the levels of J-synuclein mRNA were measured by qRT-PCR. Transcripts 
levels were normalized against cyclophilin F as an endogenous control and GAPDH 
mRNA was also quantified. As shown in Figure S1A, in absence of doxycycline expression 
of J-synuclein was dose-dependent displaying a 2 fold, 4.2 fold and 9.7 fold increase with 
2, 4l and 8l viral stock (p<0.001, F(4,40)=73.7). In presence of doxycycline (30 ng/ml), LV-
JSyn-mediated J-synuclein expression was totally abolished, and J-synuclein mRNA 
returned to basal levels (Figure S1A). GAPDH mRNA was not affected by these conditions 
showing a constant ratio of 1.3.
In order to knock-down J-synuclein expression, lentivirus-based RNA interference was 
used. Three different siRNAs were designed, targeted against three different regions of the 
J-synuclein mRNA and cloned under a U6 promoter into the transfer plasmid of the 
lentivirus system. These lentivirus constructs were not doxycycline-regulable. The three 
LV-JSyn-siRNAs were mixed at equal amounts for optimal inhibition of J-synuclein
expression, and this mix was tested in HEK293T cells overexpressing J-synuclein.
HEK293T cells were infected with 2l of LV-JSyn and co-infected with different amount of 
the mix of LV-JSyn-siRNAs (0.5, 1, 2, and 4l) and J-synuclein expression was measured 
by qRT-PCR (Figure 1B). This resulted in drastic down-regulation of J-synuclein, yielding 
residual J-synuclein mRNA levels of 46, 24, 9 and 1.6% respectively (Figure S1B, p<0.001;
F(5,24)=101.04). The expression levels of endogenous control (cyclophilin F and GAPDH) 
were not affected by LV-JSyn-siRNAs.
In vitro assay of lentivirus-mediated DAT expression in HEK 293T cells: The efficiency 
of the LV-DAT to drive DAT overexpression was also assessed in vitro. HEK293T cells 
were infected using 2, 4 or 8l of the LV-DAT stock, and the DAT mRNA was quantified 
by qRT-PCR. Cyclophilin F and GAPDH were used as endogenous control. In absence of 
doxycycline, LV-DAT infection in HEK293T cells led to titre-dependent overexpression of 











infection with 2, 4 and 8 l of LV-DAT, respectively (p<0.001, F(3,32)=64.99). GAPDH 
mRNA levels were unchanged in these conditions, displaying a constant ratio of 1.3. In 
presence of doxycycline, DAT mRNA increases were totally abolished, returning back to 
basal levels, but GAPDH mRNA levels were unaffected (Figure 1C).  
As for J-synuclein, knock-down of DAT expression was assessed using LV-DAT-siRNAs. 
For this purpose, three different siRNAs targets against the DAT mRNA were designed, 
cloned into the lentivirus system under a U6 promoter. The three LV-DAT-siRNAs were 
mixed at an equal amount for optimal DAT knock-down and tested. HEK293T cells were 
co-infected with 2l of LV-DAT and different amount of mix of LV-DAT-siRNAs (0.5, 1, 2 
and 4l). Infection with 1l mix of LV-DAT-siRNAs induces a 57% down-regulation of 
DAT expression (Figure 1D, p<0.0001; F(5; 24)= 56.05), whereas infection with 2l and 4l
mix of LV-DAT-siRNAs leads to 25% and 9% residual DAT expression levels, respectively 
(Figure 1D, p<0.0001; F(5;24)= 56.05). The expression levels of endogenous control 
(cyclophilin F and GAPDH) were not affected by LV-DAT-siRNAs. 
In vitro evaluation of target specificity of LV-siRNAs: J-Synuclein is a small protein and 
displays ca.95% homology to D-synculein. In order to test for the specificity of our LV-
JSyn-siRNA, HEK293T cells have been transfected with different closely related contructs. 
Transfection of HEK293T cells with LV-JSyn-siRNA has no effect on expression of D-
synuclein, and vice-versa transfection of LV-DSyn-siRNA do not affect J-synuclein 
expression, despite of the very high homology of the two genes (Fig.S2 and Table S1). 












In vitro Expression of Lentivirus Constructs in HEK-293T: HEK-293T cells were infected as 
indicated. After 72h, Total RNA was extracted using the Trizol method, cDNA was prepared 
and transcripts levels were quantified using real-time PCR method with specific primers. 
Control: Non-infected HEK 293 T cells. Values indicate means ±SEM.
S1A: In vitro expression of J-synuclein of HEK293T cells transfected with LV-JSyn. HEK 293T 
cells were infected with 0, 1, 2, 4, or 8l of LV-JSyn in culture medium in the presence or 
absence of doxycycline (30ng/ml) as indicated. *p< 0.05, ***p< 0.001 compared to control cells 
(non infected) 
S1B: in vitro evaluation of LV-JSyn-siRNAs efficiency in HEK 293 T cells. HEK-293T cells 
were infected with 2l of LV-JSyn alone or ci-infected with 0.5, 1, 2, or 4 l LV-JSyn-siRNAs.











S1C: in vitro expression of DAT mRNA using LV-DAT in HEK 293T cells. HEK 293T cells 
were infected with 0, 2, 4, or 8l of LV-DAT in culture medium in the presence or absence of 
doxycycline (30ng/ml) as indicated. ***p< 0.001 compared to control cells (non infected) 
S1D: in vitro evaluation of LV-DAT-siRNAs efficiency in HEK-293T cells. HEK-293T cells 
were infected with 2l of LV-DAT alone or together with 0.5, 1, 2, or 4 l of LV- DAT-












In vitro Evaluation of Target Specificity of LV-JSyn-siRNA:
HEK-293T cells were infected with 2l of LV-DSyn alone (a) or with 2l of LV-DSyn
together with either 2Pl of LV-DSyn-siRNAs (b) or with 2Pl LV-DSyn-siRNAs (c). Also cells 
were infected with 2Pl LV-JSyn alone (d) or with with 2l of LV-JSyn together with either 
2Pl of LV-JSyn-siRNAs (e) or with 2ul LV-DSyn-siRNAs (f). After 24 h incubations, cells 
were harvested and mRNA extracted and measured by qRT-PCR. Figure S2A: evaluation 
of J-synuclein mRNA; Figure S2B: evaluation of D-synuclein mRNA. See also Table S1 for 












Locomotor Activity upon DAT and J-Synuclein Overexpression or Silencing in the 
Nacc. Total distance travelled in locomotor activity from figures 1 and 2. Each bar 













Expression of DAT and J-Synuclein in the VTA upon lentivirus injection in the NAc.
S4A: Western Blot  analysis were performed as in Fig. 4 from VTA samples of animals 
treated with lentivirus injected in the NAc. Western blots from gels loaded with 20g
protein/lane were analyzed for either DAT or J synuclein expression, and reprobed with E
actin antibody to compare DAT or J synuclein expression in the VTA upon lentivirus 
infection in the NAc. 
DAT and J-Synuclein signals were estimated as in Fig. 4, using multi-anlyst software and 
normalized against E-actin signal (see Fig. 4 and Methods Section for details). Data 
represents means ±SEM. S4B: In vivo DAT protein levels quantification in the VTA. 
***p<0.001, **p<0.01: semi-quantitative DAT protein quantification vs. DAT quantification 
detected from LV-GFP injected rats S4C: in vivo J-synuclein protein levels quantification in 
the VTA. ***p<0.001, **p<0.01: semi-quantitative J-synuclein protein quantification vs. J-











S4D: High magnification immunohistochemistry of J-synuclein expression in the VTA. 
Immunohistochemistry was performed after in vivo delivery of LV-JSyn (2l) combined 
with LV-DAT (2l) (left panels) or LV-siRNA-g-syn (middle panels) or LV-GFP (right 
panels). Lentiviruses injections were performed into the Nac according to the coordinates 
described in the Methods section. Animals used for behavioral analysis were fed either 5% 
sucrose or 5% sucrose ⁄ 0.02% doxycycline (see text for details). Animals were killed at the 
end of behavioral analyses; brains were dissected out, and processed for 
immunohistochemistry (see Methods). Brain sections from animals fed 5% sucrose (upper 
panels) or doxycycline (lower panels) were labeled using antibodies against J-synuclein
and were visualized by fluorescence microscopy at 40X magnitude. 
S4E: High magnification immunohistochemistry of DAT expression in the VTA. Injections 
of LV-JSyn (2l) combined with LV-DAT (2l) (left panels) or LV-siRNA-DAT (middle 













In vitro Evaluation of Target Specificity of LV-JSyn-siRNA: HEK-293T cells were 
infected with 2l of LV-DSyn alone (a) or with 2l of LV-DSyn together with either 2Pl of 
LV-DSyn-siRNAs (b) or with 2Pl LV-DSyn-siRNAs (c). Also cells were infected with 2Pl
LV-JSyn alone (d) or with with 2l of LV-JSyn together with either 2Pl of LV-JSyn-siRNAs
(e) or with 2ul LV-DSyn-siRNAs (f). After 24 h incubations, cells were harvested, mRNA 
was extracted and measured by qRT-PCR, by evaluation of J-synuclein and of D-synuclein 
mRNA, against GAPDH as standard. See also Figure S2 for details. 
a LV-D-synuclein Average STD
D synuclein 1.516 1.625 2.297 1.813 0.423
GAPDH 0.287 0.018 0.117 0.141 0.136
J synuclein 0.001 0 0 0.000 0.001
b LV-D-synuclein+ LV-siRNAs-D-synuclein
D synuclein 0.189 0.134 0.287 0.203 0.078
GAPDH 0.379 0.047 0.088 0.171 0.181
J synuclein 0 0 0 0.000 0.000
c LV-D-synuclein+ LV-siRNAs-J-synuclein
D synuclein 1.149 2.462 2 1.870 0.666
GAPDH 0.189 0.144 0.203 0.179 0.031
J synuclein 0.005 0.033 0 0.013 0.018
d LV-J-synuclein
D synuclein 0.004 0.007 0.004 0.005 0.002
GAPDH 0.233 0.077 0 0.103 0.119
J synuclein 10.556 12.996 14.929 12.827 2.191
e LV-J-synuclein+ LV-siRNAs-J-synuclein
D synuclein 0.007 0.011 0.009 0.009 0.002
GAPDH 0.435 0.33 0.406 0.390 0.054
J synuclein 2 6.063 1.866 3.310 2.385
f LV-J-synuclein+ LV-siRNAs-D-synuclein
D synuclein 0.467 0.044 0.015 0.175 0.253
GAPDH 0.01 0.233 0.203 0.149 0.121
J synuclein 8 12.126 11.314 10.48 2.19
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